nach oben

Erschienen in:

01.07.2023 | Clinical study

No safety concerns for HepB-CpG versus HepB-alum

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Vaccination with the Dynavax hepatitis B vaccine containing the adjuvant cytosine phosphoguanine (HepB-CpG; Heplisav-B) which requires two doses does not increase the incidence of new-onset immune-mediated diseases, herpes zoster (HZ) or anaphylaxis compared with alum-adjuvanted hepatitis B vaccine (HepB-alum; Engerix-B) which requires three doses, according to findings of a Dynavax-funded postmarketing study published in Vaccine . …

Ackerson B, et al. Post-licensure safety study of new-onset immune-mediated diseases, herpes zoster, and anaphylaxis in adult recipients of HepB-CpG vaccine versus HepB-alum vaccine. Vaccine : 10 Jun 2023. Available from: URL: http://doi.org/10.1016/j.vaccine.2023.06.004

Titel: No safety concerns for HepB-CpG versus HepB-alum
Publikationsdatum: 01.07.2023
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-023-42065-x

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

No safety concerns for HepB-CpG versus HepB-alum

Excerpt

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2023

Clobazam/levetiracetam/phenytoin

Adalimumab/etanercept/infliximab

Antineoplastics

Daptomycin

Immune-globulin

Amantadine/bupropion/prednisone